<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2445D8AB-9356-4F38-88C1-6DA3176C2DC2"><gtr:id>2445D8AB-9356-4F38-88C1-6DA3176C2DC2</gtr:id><gtr:name>Findacure</gtr:name><gtr:address><gtr:line1>Findacure</gtr:line1><gtr:line2>66 Devonshire Road</gtr:line2><gtr:postCode>CB1 2BL</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F371C741-9F2B-4C24-B47A-7DB1720126C8"><gtr:id>F371C741-9F2B-4C24-B47A-7DB1720126C8</gtr:id><gtr:name>University Hospital Aachen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BECA2763-0902-40AA-8DB2-836A5731CF58"><gtr:id>BECA2763-0902-40AA-8DB2-836A5731CF58</gtr:id><gtr:name>Brunel University</gtr:name><gtr:address><gtr:line1>Brunel University</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>UB8 3PH</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8044C2F3-70A8-44B3-A919-3A5ADEFD2311"><gtr:id>8044C2F3-70A8-44B3-A919-3A5ADEFD2311</gtr:id><gtr:name>Francis Crick Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D48FC12-E560-4B37-9CF3-48B80B7FF457"><gtr:id>8D48FC12-E560-4B37-9CF3-48B80B7FF457</gtr:id><gtr:name>Institute of Genetics, Molecular and Cellular Biology (IGBMC)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2445D8AB-9356-4F38-88C1-6DA3176C2DC2"><gtr:id>2445D8AB-9356-4F38-88C1-6DA3176C2DC2</gtr:id><gtr:name>Findacure</gtr:name><gtr:address><gtr:line1>Findacure</gtr:line1><gtr:line2>66 Devonshire Road</gtr:line2><gtr:postCode>CB1 2BL</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F371C741-9F2B-4C24-B47A-7DB1720126C8"><gtr:id>F371C741-9F2B-4C24-B47A-7DB1720126C8</gtr:id><gtr:name>University Hospital Aachen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BECA2763-0902-40AA-8DB2-836A5731CF58"><gtr:id>BECA2763-0902-40AA-8DB2-836A5731CF58</gtr:id><gtr:name>Brunel University</gtr:name><gtr:address><gtr:line1>Brunel University</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>UB8 3PH</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8044C2F3-70A8-44B3-A919-3A5ADEFD2311"><gtr:id>8044C2F3-70A8-44B3-A919-3A5ADEFD2311</gtr:id><gtr:name>Francis Crick Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D48FC12-E560-4B37-9CF3-48B80B7FF457"><gtr:id>8D48FC12-E560-4B37-9CF3-48B80B7FF457</gtr:id><gtr:name>Institute of Genetics, Molecular and Cellular Biology (IGBMC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6F3C80C5-1E93-4E7B-A050-C6C768F1632C"><gtr:id>6F3C80C5-1E93-4E7B-A050-C6C768F1632C</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Festenstein</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U120081321"><gtr:id>BD4F8FCC-211D-4E8A-BC81-49CB555FA921</gtr:id><gtr:title>Gene Control Mechanisms and Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U120081321</gtr:grantReference><gtr:abstractText>Although nearly every cell contains two copies of every gene, different types of cells have distinct features. As we are made from billions of cells how is the genetic information controlled? Clearly, not all genes are active in all cells. Our research focuses on how different cells know to switch on some genes but not others. It is now clear that this involves packaging the genes in different ways in the nucleus. Between the genes themselves, which are made of DNA, are non-coding DNA sequences that control whether the gene is on or off in a particular cell. We have shown that some sequences can open the DNA allowing the nearby gene to switch on whereas other sequences have the opposite effect and close the DNA into a densely packaged compartment. There are many proteins that package the DNA, we have shown that we can affect the probability of switching genes on or off by including repetitive DNA close by to the gene or by changing the amount of packaging proteins available. We think that this is what happens in some neurological diseases. Using transgenic mice we have shown that we could reverse this abnormal silencing. This finding opens up new possibilities for treating as yet incurable diseases. We are presently focusing on several examples, including the neurodegenerative disease Friedreichs ataxia, and have shown that we can reverse abnormal silencing in cells from patients with this disease. Such an approach could lead to a treatment. Our work will also shed light on how males apparently can switch some genes off more easily than females. Such information is important for understanding why some diseases might affect the sexes differently. Our research is on the fundamentals of how cells regulate genes during development and is therefore likely to reveal crucial information as to how stem cells can replace a variety of different cell types and stably maintain the correct gene regulation in these cells.</gtr:abstractText><gtr:technicalSummary>Our research is aimed at unravelling the molecular mechanisms underlying epigenetic memory in mammals whereby cells establish and maintain gene expression patterns, and at understanding how dysregulation at this level leads to human diseases. Such research is crucial for the development of novel treatments for several diseases by modulating chromatin structure and for the development of reliable gene therapy protocols as well as understanding the plasticity of stem cells. The research builds on our finding that a gene-regulatory element known as a locus control region (LCR) can overcome gene silencing mediated by proximity to highly repetitive heterochromatic genomic regions. We have shown that in the absence of the LCR such silencing strongly resembles the archetypal epigenetic phenomenon of position effect variegation (PEV), hitherto demonstrated in Drosophila and yeast. By studying modifiers of PEV in an in vivo mammalian system we have shown that aberrant silencing associated with several triplet-repeat diseases occurs at the level of heterochromatin and can be reversed in vivo; such silencing can not only be reversed by an LCR but can also be overcome by drugs known to modify chromatin structure. Recently we have uncovered important differences in the extent of heterochromatin silencing in male and female mice which is not determined by the gender of the mice but rather the number of X chromosomes - this finding has implications for understanding sexual dimorphism, a feature of many diseases, which is usually attributed to the male or female phenotypes. Our work currently focuses on the interplay between nuclear organisation, chromatin structure and epigenetic modifiers in establishing and maintaining the differentiated state of the cell. Our recent finding that a key component of the densely packaged form of DNA known as heterochromatin is in a continuous state of flux has shattered the previously held view that heterochromatin acted as a molecular glue. Our finding opens up the possibility of re-programming the genome even in so-called inaccessible heterochromatin regions. We are currently investigating the reversibility of such silencing in the neurological disease Friedreichs ataxia; this promises to provide a radical approach for treating this currently incurable condition.</gtr:technicalSummary><gtr:fund><gtr:end>2012-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3351210</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Aachen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>NICOFA -E-rare funding for randomised controlled study for nicotinamide in Friedreich's ataxia</gtr:description><gtr:id>9A3FAB1D-D848-4F4F-BFD4-7D6788F13F2D</gtr:id><gtr:impact>E-rare funding granted. EME proposal - full proposal invited.</gtr:impact><gtr:outcomeId>58caa5ad665b62.10008982-1</gtr:outcomeId><gtr:partnerContribution>The partners have secured funding from a transnational E-rare funded collaboration. We are seeking funding from the MRC/NIHR EME scheme to fund the UK arm of the controlled trial.</gtr:partnerContribution><gtr:piContribution>We have discovered that the aberrant gene silencing that occurs in Friedreich's ataxia causing the disease can be overcome in patients. This suggests that long-term treatment with nicotinamide would be expected to ameliorate disease progression in this frequently devastating and, so far, incurable disease. This study which was published in the Lancet has seeded further collaborations across EUrope to secure enough patients for a placebo controlled study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Francis Crick Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>JT</gtr:description><gtr:id>EED8A5F0-74D6-4A22-9EBD-D83F53640459</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:outcomeId>58c944adac21b6.37480105-1</gtr:outcomeId><gtr:partnerContribution>Obtaining genetically altered mice to analyse for effects on sexually dimorphic gene expression is enabling the molecular dissection of how in early deveelopment heterochromatin components have a dimorphic effect.</gtr:partnerContribution><gtr:piContribution>Collaboration with JT allows examination of the contribution of genes on the Y chromosome to sexually dimorphic autosomal gene expression</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brunel University London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Health Sciences and Social Care</gtr:department><gtr:description>MP</gtr:description><gtr:id>2689E406-61D2-46E1-85EA-7A206A4E2DF4</gtr:id><gtr:impact>The data is in preparation for publication but has partly seeded an MRC DPFS grant</gtr:impact><gtr:outcomeId>06C6249CF07-1</gtr:outcomeId><gtr:partnerContribution>Provision of human frataxin transgenics providing mouse model of Friedreich's ataxia</gtr:partnerContribution><gtr:piContribution>We analysed the mice for histone modifications at the Frataxin locus to determine the molecular pathogenesis underlying the aberrant silencing which results in the disease</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Genetics and Molecular and Cellular Biology (IGBMC)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>FC</gtr:description><gtr:id>1EC2A279-5F43-4E69-AC3A-F405CA8D0DD9</gtr:id><gtr:impact>We found that the coactivator regulates the mobility of its interacting partner and modulates the stability of heterochromatin and the stability of gene silencing. Manuscript in preparation</gtr:impact><gtr:outcomeId>989816CA9AA-1</gtr:outcomeId><gtr:partnerContribution>Provision of murine reagents enabling the conditional deletion and mutation of a co-activator molecule</gtr:partnerContribution><gtr:piContribution>We analysed the effect of disrupting the interaction between a factor which targets heterochromatin-mediated silencing to genes in vivo.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Babraham Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>WR</gtr:description><gtr:id>185EEB2E-584D-4181-8ED0-E68C2156C9C0</gtr:id><gtr:impact>We discovered that the balance between chromatin modifiers can regulate the distribution of the silencing machinery in the nucleus in vivo in mammals</gtr:impact><gtr:outcomeId>1C97D3BF146-1</gtr:outcomeId><gtr:partnerContribution>We investigated the heterochromatin-nucleating properties of a densely methylated DNA repeat sequence associated with the Igf2 locus disscovered at Babraham</gtr:partnerContribution><gtr:piContribution>We generated transgenic murine model to demonstrate that the direct repeat associated with the Igf2 locus could initiate heterochromatin-formation at multiple sites in the mouse genome.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Sciences Centre (CSC)</gtr:department><gtr:description>MU</gtr:description><gtr:id>37B14212-9C08-4741-A5C1-EA2644222BB0</gtr:id><gtr:impact>We have discovered a specific ion channel which functions abnormally in genetic mouse models of Parkinson's Disease leading to increased vulnerability of the neuron. This is therefore a potential novel therapeutic target.</gtr:impact><gtr:outcomeId>EABFF2809B7-1</gtr:outcomeId><gtr:partnerContribution>Provided neurophysiological expertise to co-supervise a PhD student</gtr:partnerContribution><gtr:piContribution>PI cosupervised a student to extend an existing project initiated in our lab on Parkinson's disease using murine models</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>X-inactivation</gtr:description><gtr:id>28B9D138-BE03-4640-98BB-9A020F79246B</gtr:id><gtr:impact>The research is in progress with no direct outcomes yet.</gtr:impact><gtr:outcomeId>58c943b1676792.01878624-1</gtr:outcomeId><gtr:partnerContribution>We have discovered a hitherto hidden layer in the regulation of sexual dimorphism in gene expression at the epigenetic level. We are using a model system developed by our collaborator to gain insight into the molecular mechanism</gtr:partnerContribution><gtr:piContribution>Collaborating on the hypothesis that the inactive X-chromosome might be attracting heterochromatin proteins and thereby regulating sexually dimorphic gene expression</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Sciences Centre (CSC)</gtr:department><gtr:description>AP</gtr:description><gtr:id>88AC9FF0-29BD-41BC-8633-EA8CEED33A37</gtr:id><gtr:impact>This work identified a novel mode of gene regulation which is perturbed in Friedreich's ataxia and indentified a novel therapeutic target.</gtr:impact><gtr:outcomeId>EA47154E73D-1</gtr:outcomeId><gtr:partnerContribution>Provided expertise in RNAPolII function</gtr:partnerContribution><gtr:piContribution>We extensively analysed the epigenetic marks and proteins bound to the Frataxin locus in Friedreich's ataxia and indentified abnormal bhaviour of RNAPolII at the locus</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC London Institute of Medical Sciences</gtr:department><gtr:description>JG</gtr:description><gtr:id>B9FAFDAE-637D-4512-B71A-9AE62655460D</gtr:id><gtr:impact>These studies are in progress.</gtr:impact><gtr:outcomeId>58c945b6afa7a8.39673673-1</gtr:outcomeId><gtr:partnerContribution>JG has all the necessary prtocols set up to examine the senscent phenotype in detail and is haring expertise</gtr:partnerContribution><gtr:piContribution>We have discovered potential sex-dimorphism in the regulation of cellular proliferation which is regulated by a heterochromatin component. The collaboration is allowing us to determine whether these gene expression changes result in an altered pronesity to senescence.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Findacure</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Findacure</gtr:description><gtr:id>ADA49404-6735-4FFB-8201-DF72525B58A0</gtr:id><gtr:impact>This is a mutli-disciplinary projkect pulling together economics and health researchers</gtr:impact><gtr:outcomeId>58caa3d1402ad2.92122453-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators provided methodology to model the economics of costs for looking after patients with Friedreich's ataxia</gtr:partnerContribution><gtr:piContribution>Investigation with Findacure to calculate the cost benefits of reversing pathology in Friedreich's ataxia in order to make the case for funding a clinical trial of a novel disease modifying strategy in this disease</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Webinar Ataxia UK</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C0D9B50C-37F9-4C60-A15D-A7F224926E62</gtr:id><gtr:impact>Triggered many questions and comments relating to the next stage of our research

After the webinar I was given advice from experts on how to conduct a clinical trial for efficay of our novel treatment for Friedreich's ataxia</gtr:impact><gtr:outcomeId>5464796e038b74.44852955</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV-interview Dublin</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>440EAC1E-073E-46C5-810C-66E1DF0B4258</gtr:id><gtr:impact>Interviewed at International conference for Friedreich's Ataxia

Raised the profile of the need for research in triplet-repeat diseases</gtr:impact><gtr:outcomeId>EBF11CCDC95</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV documentary</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D709698B-181D-4F18-93B9-1EEE23FF5D53</gtr:id><gtr:impact>Interviewed for EU funded TV documentarty on Epigenetics

Communicated key ideas to a large lay audience</gtr:impact><gtr:outcomeId>AAAFDEF0DB0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Epigenomics of Common Diseases Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>765568AC-9CF9-430E-916B-F033ECFA1C89</gtr:id><gtr:impact>Presentation of the finding that a major epigenetic regulator is crucial for regulating sexual differences before sex hormones kick in.</gtr:impact><gtr:outcomeId>58c94aed3a9b32.99337127</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://conf.hinxton.wellcome.ac.uk/advancedcourses/ECD2016Programme.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Gordon Conference in Chromatin Structure and Function</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>02D949AD-7111-4D7B-9063-486C28812DC8</gtr:id><gtr:impact>Forum for experts in the field of chromatin and gene regulation to exchange unpublished data in order to further excellence in Science. This is a competitive leading conference in the field.</gtr:impact><gtr:outcomeId>58c9472362d6d2.28765097</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Epigenesys Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3918FF70-6F16-4489-BA2E-DE4F7F0905D4</gtr:id><gtr:impact>Invited speaker at European Network to present novel results showing that a key component of heterochromatin is essential for sex differences very early on in development</gtr:impact><gtr:outcomeId>58c94981a68042.94260602</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Imperial Biomedical Research Centre</gtr:department><gtr:description>BRC Imperial</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>8608024E-D3DA-4365-9CAB-4E934CC8472A</gtr:id><gtr:outcomeId>EaigT4oxQfx</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>118000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Project Grant Freidreich's ataxia</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Ataxia UK</gtr:fundingOrg><gtr:id>537EA8F7-F4D5-430E-AAE7-54C946FB15F1</gtr:id><gtr:outcomeId>fmy3C5L61Fv</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>351000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Developmental Pathway Funding Scheme (DPFS)</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DD1EDED1-0CF8-427C-819D-0ABD97356B9A</gtr:id><gtr:outcomeId>7BCECE58AF00</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>863446</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Response mode project grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A6932375-D381-43AD-9458-F098F095F305</gtr:id><gtr:outcomeId>Pt6Txwf3emz</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>0</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>A randomized double-blind placebo-controlled parallel-group multi-centre study of the efficacy and safety of nicotinamide in patients with Friedreich's ataxia (NICOFA)</gtr:description><gtr:end>2020-10-02</gtr:end><gtr:fundingOrg>E-Rare</gtr:fundingOrg><gtr:id>9CDD2316-FF69-45A9-B40A-29336BDB4678</gtr:id><gtr:outcomeId>58ac2edc5c4715.09068548</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We have found that particular histone deacetylase inhibitors can upregulate the aberrantly silenced Frataxin gene which is repressed in Friedreich's ataxia.</gtr:description><gtr:grantRef>MC_U120081321</gtr:grantRef><gtr:id>62BEBA33-7182-463D-976F-142145B1F6B0</gtr:id><gtr:impact>This has resulted in ourselves and opthers developing novel therapeutics which are undergoing testing in mouse models for Friedreich's ataxia.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>51438F3F59B</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Identified potential therapeutic targets and therapies for Friedreich's ataxia</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Identification of an HDAC inhibitor that can upregulate Frataxin in cells from patients with Friedreich's ataxia</gtr:description><gtr:id>C091CBAF-A2CA-493A-A073-D0E42945EA40</gtr:id><gtr:impact>Potential as a therapeutic for Friedreich's ataxia which is currently incurable</gtr:impact><gtr:outcomeId>rBkxxrTtSSZ</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HDACi therapy for FRDA</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Having shown that the GAA-triplet repeat expansion which occurs in the neurodegenerative disease, Friedreich's ataxia, can induce heterochromatin-mediated silencing we identified histone deacetylase inhibitors that can overcome such silencing in cells from patients.
This has recently been tested in a proof-of-concept study (Libri et al Lancet 2014)</gtr:description><gtr:id>C72FF3FF-43B5-4DBF-A67D-D9EBBE5739FF</gtr:id><gtr:impact>We are investigating this finding as a potential treatment with help from an MRC DPFS grant and support from Ataxia UK and the EU FP7 programme.</gtr:impact><gtr:outcomeId>444293E494E</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>HDACi</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Developing methodology to analyse behaviourmetric data in Friedreich's ataxia</gtr:description><gtr:id>88EFF177-44BE-42A9-A6C7-29CCE2F6BE9C</gtr:id><gtr:impact>The main impact promises to shorten the length of clinical trials by providing a more robust biomarker for disease progression by measuring movements during everyday living.</gtr:impact><gtr:outcomeId>58af0d4a6938d8.34519290</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Motion Capture Suit analytics</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Established a murine model to enable chromatin immunoprecipitation and purification of protein complexes using a biotin-tagged version of heterochromatin-protein 1 expressed in vivo.</gtr:description><gtr:id>B02AF059-81AC-4D3E-9B1F-F0E58BCB3DD1</gtr:id><gtr:impact>Will enable epigenomic maps to be established for this protein using ex vivo tissue circumventing technical problems the field has faced related to use of antibodies for this purpose.</gtr:impact><gtr:outcomeId>D4EA35E5C9A</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HP1beta-bio</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Epigenome bioinformatics tool to visualise gene expression profiles simulataneously with genome-wide data provided by chromatin immunoprecipitation.</gtr:description><gtr:id>351EE764-85F7-4C2C-A86F-B58E260B8496</gtr:id><gtr:impact>Has allowed rapid identification an interrogation of regions of the genome responding to epigenetic modifiers</gtr:impact><gtr:outcomeId>2119E17128C</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>TROY</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Polyclonal antibody specific to histone H3 lysine 4 acetylation</gtr:description><gtr:id>6C8D24D3-5F25-45F3-B7E3-6B24BC83E78B</gtr:id><gtr:impact>Identification that histone H3 is modified on a key residue, lysine 4, in yeast and mammals. This changes our understanding of how gene's are regulated in eukaryotes as indicated by our genome-wide epigenomic and functional studies.</gtr:impact><gtr:outcomeId>8E6B8B94917</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Identification of histone H3 K4acetylation as a novel post-translational modification using a novel antibody</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Set-up database for patients suffering from Friedreich's ataxia</gtr:description><gtr:id>B6424B8A-9160-473A-AA6B-706A8520A136</gtr:id><gtr:impact>Obtained PBLs, chromatin and RNA inorder to perform epigenotype/phenotype correlations.</gtr:impact><gtr:outcomeId>D45ED8E529E</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>FRDA cohort</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Murine model to explore function of key chromatin component.</gtr:description><gtr:id>5FF57F5D-9A2E-473C-81C7-27D80E593A2E</gtr:id><gtr:impact>Established that this modifier is a potential modifier of heterochromatin-mediated silencing and triplet-repeat diseases.</gtr:impact><gtr:outcomeId>AA423311E63</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HP1gamma transgenics</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Inserted the triplet-repeat expansion associated with the commonest adult onset muscular dystrophy (Myotonic Dystrophy) into the cognate mouse locus to model the gene expression defect.</gtr:description><gtr:id>116F0C43-2BE3-4729-B051-462F7D27F277</gtr:id><gtr:impact>Established improved tractable model for studying gene expression perturbations in triplet-repeat diseases in vivo.</gtr:impact><gtr:outcomeId>9D3B5B1ECA2</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CTG -transgenics</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6D380D81-FA64-463F-B7A2-5A2FE3C21FDF</gtr:id><gtr:title>Epigenetic regulation of autosomal gene expression by sex chromosomes.</gtr:title><gtr:parentPublicationTitle>Trends in genetics : TIG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/426d2cb8064891b0c23192d645b8ef7c"><gtr:id>426d2cb8064891b0c23192d645b8ef7c</gtr:id><gtr:otherNames>Wijchers PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-9525</gtr:issn><gtr:outcomeId>NCoG5o2rGF7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2CBDF65-52C6-4F97-9E96-D75E911ACE05</gtr:id><gtr:title>Transcriptional Activation of Pericentromeric Satellite Repeats and Disruption of Centromeric Clustering upon Proteasome Inhibition.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5a21edf7aa599b656b0f8d115a0da83"><gtr:id>f5a21edf7aa599b656b0f8d115a0da83</gtr:id><gtr:otherNames>Natisvili T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d6300d38db1.69255996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D2B6A08-CD50-4C68-AB2B-8A41A54FE706</gtr:id><gtr:title>Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b8300fec9520728389469052e9be7f5"><gtr:id>8b8300fec9520728389469052e9be7f5</gtr:id><gtr:otherNames>Chan PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_14037_27_23474817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>897625F0-56F8-42D7-8C1E-2CD122FE765F</gtr:id><gtr:title>Context is everything: activators can also repress.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0354e961de8472449451b121e8d7022a"><gtr:id>0354e961de8472449451b121e8d7022a</gtr:id><gtr:otherNames>Festenstein R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>pm_14037_27_23037592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5056E7D-3180-4EAA-BAC9-D6D714767C35</gtr:id><gtr:title>H3 lysine 4 is acetylated at active gene promoters and is regulated by H3 lysine 4 methylation.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d489acdd72e8dc0a1791df6383a55df"><gtr:id>1d489acdd72e8dc0a1791df6383a55df</gtr:id><gtr:otherNames>Guillemette B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>Ug7RqGfqtWt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>526BE66F-5C3A-457F-BF2B-C2994BE502A0</gtr:id><gtr:title>Gene regulation and epigenetics in Friedreich's ataxia.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58930643724f065f0517d82550e47364"><gtr:id>58930643724f065f0517d82550e47364</gtr:id><gtr:otherNames>Yandim C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>pm_14037_27_23859339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C58BA4A3-2AD1-4148-9BD7-4DA338AAD7B9</gtr:id><gtr:title>Tissue-dependent regulation of RNAP II dynamics: the missing link between transcription and trinucleotide repeat instability in diseases?</gtr:title><gtr:parentPublicationTitle>Transcription</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5347bc9353596d38395097060bc39cc8"><gtr:id>5347bc9353596d38395097060bc39cc8</gtr:id><gtr:otherNames>Goula AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2154-1272</gtr:issn><gtr:outcomeId>pm_14037_27_23989661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6A280B3-5A5C-4C05-8E27-F53110398B58</gtr:id><gtr:title>Continuous Histone Replacement by Hira Is Essential for Normal Transcriptional Regulation and De Novo DNA Methylation during Mouse Oogenesis.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/762a0c0b19f3d13747de8b78ebc0845f"><gtr:id>762a0c0b19f3d13747de8b78ebc0845f</gtr:id><gtr:otherNames>Nashun B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>56def63b5ffc58.11947076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F383AAD3-E1DB-4407-BDCB-7307813644F8</gtr:id><gtr:title>Towards neurobehavioral biomarkers for longitudinal monitoring of neurodegeneration with wearable body sensor networks</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/351e71c4c5d9187b963a7bc9afdb6504"><gtr:id>351e71c4c5d9187b963a7bc9afdb6504</gtr:id><gtr:otherNames>Gavriel C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56c2f715413665.94307000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DC5EBE3-A6FA-4C60-B23D-97EB360597DB</gtr:id><gtr:title>Sexual dimorphism in mammalian autosomal gene regulation is determined not only by Sry but by sex chromosome complement as well.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/426d2cb8064891b0c23192d645b8ef7c"><gtr:id>426d2cb8064891b0c23192d645b8ef7c</gtr:id><gtr:otherNames>Wijchers PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>c7mhwtikzxJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F6DAD33-083C-412A-8978-E73D4502BBFA</gtr:id><gtr:title>Kinematic body sensor networks and behaviourmetrics for objective efficacy measurements in neurodegenerative disease drug trials</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/351e71c4c5d9187b963a7bc9afdb6504"><gtr:id>351e71c4c5d9187b963a7bc9afdb6504</gtr:id><gtr:otherNames>Gavriel C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56c2f82cbc5966.37935483</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B00CFA9-8DCD-40E4-8065-7303F7D88786</gtr:id><gtr:title>OVERCOMING TRIPLET REPEAT-MEDIATED EPIGENETIC SILENCING IN HUMANS</gtr:title><gtr:parentPublicationTitle>JOURNAL OF INTELLECTUAL DISABILITY RESEARCH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d82c3d6b48ead8b230692fb36ac055c5"><gtr:id>d82c3d6b48ead8b230692fb36ac055c5</gtr:id><gtr:otherNames>Festenstein R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-2633</gtr:issn><gtr:outcomeId>56c2f7b3f409e7.76918931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC5C4B0E-6818-4C6A-8B5D-BA6528BF3AE8</gtr:id><gtr:title>Epigenetics and Triplet-Repeat Neurological Diseases.</gtr:title><gtr:parentPublicationTitle>Frontiers in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/416a2bfe7f6ec3c527fe94ee6df74edd"><gtr:id>416a2bfe7f6ec3c527fe94ee6df74edd</gtr:id><gtr:otherNames>Nageshwaran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-2295</gtr:issn><gtr:outcomeId>56c2e97ba18d16.71870133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42DBEA63-FAE1-4DD4-B2A3-BBF2171A0C76</gtr:id><gtr:title>Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d4abefe8b50cd360610b80cdf07d3f6"><gtr:id>9d4abefe8b50cd360610b80cdf07d3f6</gtr:id><gtr:otherNames>Libri V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>54621b4f9e9d25.37555979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51BC0F5E-C9A2-4862-B6E1-2120960A3E21</gtr:id><gtr:title>Transcription elongation and tissue-specific somatic CAG instability.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5347bc9353596d38395097060bc39cc8"><gtr:id>5347bc9353596d38395097060bc39cc8</gtr:id><gtr:otherNames>Goula AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>pm_14037_27_23209427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F7AB22E-4D54-4A0D-A085-2894781444D1</gtr:id><gtr:title>Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice.</gtr:title><gtr:parentPublicationTitle>Journal of neurophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6f617d73d5718ae5f7d8b84c2cea297"><gtr:id>c6f617d73d5718ae5f7d8b84c2cea297</gtr:id><gtr:otherNames>Bishop MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3077</gtr:issn><gtr:outcomeId>gtgSC9tLmHi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78FA8FD3-BB05-4C41-83D8-1653B535AD44</gtr:id><gtr:title>The molecular basis for stability of heterochromatin-mediated silencing in mammals.</gtr:title><gtr:parentPublicationTitle>Epigenetics &amp; chromatin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/011123e0f0e5e6d44a129614d1c92aef"><gtr:id>011123e0f0e5e6d44a129614d1c92aef</gtr:id><gtr:otherNames>Hiragami-Hamada K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1756-8935</gtr:issn><gtr:outcomeId>1FA20F6288A</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U120081321</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>